{
  "name" : "moscow.sci-hub.se_5154_6024ff7a8ad18757d3971bc685562dce_vecchione2016.pdf",
  "metadata" : {
    "source" : "META",
    "title" : "Curcumin bioavailability from oil in water nano-emulsions: In vitro and in vivo study on the dimensional, compositional and interactional dependence",
    "authors" : [ "Raffaele Vecchione", "Vincenzo Quagliariello", "Dominic Calabria", "Vincenzo Calcagno", "Elisa De Luca", "Rosario V. Iaffaioli", "Paolo A. Netti" ],
    "emails" : [ "Care@CRIB,", "Nanotechnologies@UniLe,", "paolo.netti@iit.it;", "r.iaffaioli@istitutotumori.na.it;" ],
    "sections" : [ {
      "heading" : null,
      "text" : "AC C\nEP TE\nAlthough nanocarriers can enhance the bioavailability of free curcumin in the blood, a systematic study on the parameters that affect such enhancement is still missing. In this work we focused the attention on a nanocarrier represented by an oil in water nano-emulsion coated with a thiol modified chitosan and carried out a comprehensive study on the effects that parameters such as size, co-delivery of piperine and degree of chitosan modification can exert on curcumin bioavailability and quantified their impact. We obtained an unprecedented pharmacokinetic profile of curcumin with the best formulation, represented by a combination of a small nanoemulsion size (110 nm), co-delivery of curcumin and piperine (weight ratio 100:1) and a high degree of chitosan thiolation (14-15%). Then, we assessed its anti-inflammatory properties after oral administration in rats at low doses (≤ 0.1 times the volume administered in the pharmacokinetic study). Furthermore, the proposed food grade nano-emulsions loaded with curcumin did not show any cytotoxic effect on normal fibroblasts, while they were able to promote death in colon cancer cells in agreement with the common knowledge of the selective action of curcumin.\nKeywords: curcumin; piperine; nano-emulsions; chitosan; 2-iminothiolane; colon cancer."
    }, {
      "heading" : "1. Introduction",
      "text" : "Curcumin, a bioactive compound isolated from the rhizome of the Curcuma longa plant, has a long history of use in traditional Chinese and Indian medicine. An interesting example concerns the common use of curcumin\nAC C\nEP TE\nD M\nAN U\nSC R\nIP T\nElsevier 2\npowder for the treatment of cough and related respiratory diseases [1] and as an antidysenteric [2]. Moreover, in the past, it was also used to treat dental diseases, digestive disorders such as dyspepsia and acidity, indigestion, flatulence, ulcers and many inflammatory conditions in different body regions [3]. From a chemical point of view, curcumin is a diferuloyl methane molecule [1,7-bis (4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5dione)] containing two ferulic acid residues joined by a methylene bridge. Curcumin acts as a ROS scavenger, increases antioxidant glutathione levels by induction of glutamate cysteine ligase, and acts as an antiinflammatory agent through the inhibition of NF-κB signaling [4]. It acts through the inhibition of I-κB phosphorylation and thus prevents I-κB degradation by the proteosomes. Despite its numerous applications, the most relevant issues concerning the pharmacokinetics of curcumin are: molecular instability, poor solubility in water, rapid conjugation to hydrophilic molecules (like glucuronic acid and sulphate) in the liver with biliary excretion and poor enteral absorption [5]. To increase its bioavailability, several approaches have been tried: phospholipid complexes (phytosomes), which increased the area under the blood concentration-time curve (AUC) of curcumin after oral administration in rats by 5 times [6]; association with cyclodextrin, with a ten-fold increase in curcumin AUC [7]; BCM-95 extract, whose bioavailability in rats was 7.8 times higher than unformulated curcumin [8]; mixing of curcumin with an essential oil obtained from standardized turmeric where AUC was 7–8 times higher than unformulated curcumin [9]. Another interesting approach to improve the biodistribution of curcumin is based on its combination with piperine, the alkaloid responsible for the pungency of black pepper and long pepper; it inhibits the glucuronidation processes by the enzyme UDP-glucuronosyltransferase (with Ki of 70 µM) in the liver and small intestine, as demonstrated by the administration of unformulated curcumin and piperine [10, 11]. It is also known that oil in water nano-emulsions can provide an anti-inflammatory action as a response to the bioavailability of free curcumin in the blood [12]. The best performing nano-emulsion produced so far has provided no more than a ten-fold increase in the AUC compared to unformulated curcumin in mice [13]. The best performing system has been up to now based on the use of colloidal curcumin nanoparticles, named 'theracurmin' that showed AUC after oral administration 40-fold higher than that of curcumin powder in rats [14]. Motivated by the very interesting properties of curcumin, in our study we proposed an easily tunable nanocarrier in order not only to find out optimal conditions to further enhance curcumin bioavailability, but also to better understand the impact of different nanocarrier parameters to address the design of more and more performing nanocarriers. In particular, we developed and tested biologically, in vitro and in vivo, a new nanometric formulation of curcumin combined with the alkaloid piperine, both loaded in oil in water nanoemulsions stabilized by a layer of chitosan chosen for its resistance to the gastro tract and adhesive properties towards the intestinal lumen [15]. Due to the enhanced adhesive properties of the chitosan derivative possessing thiol moieties [16], we optimized the degree of functionalization of chitosan with 2-iminothiolane and tested the system at different degrees of functionalization to quantify its impact. Emulsion size is another important parameter to investigate; although most of the studies report bioavailability improvement with a reduction in nanocarrier size [17, 18], there is evidence that -in some cases- size plays a minor role [19]. In this context, we analyzed the effects of size on the bioavailability of free curcumin by using a first emulsion with a 110 nm diameter and a second circa double in size. In combination with the pharmacokinetic study we also carried out a biodistribution analysis and evaluated the cytotoxic effect of the curcumin loaded nano-emulsion on normal fibroblasts and on colon cancer cells to assess curcumin activity upon encapsulation in our nanocarrier. Finally, to assess the efficacy of the proposed nanotool, as a functional test, we tested the anti-inflammatory properties of the best formulation on lipopolysaccharide (LPS) treated rats in comparison with a traditional lipid formulation based on curcumin phosphatidylcholine complexation at different volume doses, including volumes compatible with a possible transfer to humans.\nAC C\nEP TE\nD M\nAN U\nSC R\nIP T\nElsevier\n3"
    }, {
      "heading" : "2. Materials and Methods",
      "text" : "2.1. Materials\nOil in water nano-emulsions were obtained by using a formulation based on pharma grade products such as soybean oil and Lipoid E80 lecithin, both purchased from Lipoid and used without further purification. Millipore® Milli-Q water was used for the preparation of all emulsions and solutions. The emulsions were then coated with chitosan (CT, LMW 90-150 kDa, DD 84% determined via 1H-NMR) also purchased from Sigma-Aldrich and purified before use [20]. For the in fluorescence analysis, chitosan was chemically labelled with Fluorescein 5(6)- isothiocyanate (FITC, m.w.=389.38 g/mol) purchased from Sigma Aldrich. 1,4-diazabicyclo[2.2.2]octane (dabco) (m.w.=112.17 g/mol), antifade, also purchased from Sigma Aldrich, was used to avoid the bleaching phenomenon of FITC. Optical dishes FD3510 (from World Precision Instruments) with a cover glass bottom were used to allow STED observation of the samples. Curcumin (from Curcuma longa (Turmeric), powder, m.w.=368.38) and piperine (97%, m.w.=285.34) were both purchased from Sigma-Aldrich and used with no further purification. 2-Iminothiolane hydrochloride (2-IT), DL-Dithiothreitol (DTT), deuterium oxide (D2O), trifluoroacetic acid (TFA), 5,5’-dithiobis(2-nitrobenzoic acid) (DTNB, also known as Ellman’s reagent) were also purchased from Sigma Aldrich while dialysis membranes (12-14 kDa MWCO) from Spectrum Laboratories, Inc. and used during the phases of functionalization and characterization of the chitosan. For cellular studies Dulbecco's Modified Eagle's Medium (DMEM) and McCoy’s 5A medium were obtained from Sigma Aldrich, instead Fetal Bovine Serum (FBS), Penicillin/Streptomycin (10000 U/ml) and Glutamine were purchased from Invitrogen, Life Technologies. For pharmacokinetic and anti-inflammatory studies, Proteinase k and Lipopolysaccharide (LPS) were obtained from Sigma-Aldrich.\n2.2. Synthesis of CT-IT\nChitosan Low Molecular Weight (CT-LMW, 100 mg, 0.50 mmol) was dissolved in 10 ml of 0.1 M of acetic acid solution. After complete dissolution, pH was adjusted to 6 with NaOH. 2-iminothiolane hydrochloride (2-IT, 40 mg, 0.30 mmol in one case and 20 mg, 0.15 mmol in the other case) were added and pH was further adjusted to 6.5 with NaOH and HCl. The reaction proceeded under magnetic stirring and at room temperature overnight. After reaction, DL-Dithiothreitol (DTT, 40 mg, 0.25 mmol) was added and left to react for 1 h. Then the pH was adjusted to 3.5 with HCl and the sample was dialyzed (dialysis tubing with 12-14 KDa Cut-Off) and freeze-dried for 48 h. Eight dialysis cycles were executed: 4 cycles with NaCl 1% w/v pH 3 water solution, and 4 cycles with pH 3 water solution. Samples were characterized with 1H NMR spectroscopy and the amount of free thiols was evaluated with the Ellman’s test [20].\n2.3. Synthesis of CT-FITC\nChitosan Low Molecular Weight (CT-LMW, 100 mg, 0.50 mmol) was dissolved in 10 ml of 0.1 M of acetic acid solution. After complete dissolution, a solution of FITC (5.0 mg in 500 µl of DMSO) was added dropwise. The reaction proceeded overnight at room temperature. Sample was then precipitated adjusting the pH to 10 with\nAC C\nEP TE\nD M\nAN U\nSC R\nIP T\nElsevier 4\nNaOH and the precipitate was collected by centrifuge (9000 rpm, 15 min). Sample was washed with water by means of several centrifugations, until negligible fluorescence was detected in the supernatant (using Perkin Elmer 2300 Enspire Plate Reader, λex = 488 nm, λem = 510 nm). Finally, the purified product was freeze-dried for 48 h.\n2.4. Sample preparation and characterization\nThe systems proposed in this work are mainly based on nano-emulsions coated with chitosan; however, other formulations were also used as a control. Two different sizes of nano-emulsions were prepared depending on the amount of surfactant, Lipoid E 80, dissolved in soy-bean oil and for each size we prepared two different carriers, one with curcumin and one with piperine. In particular, 5.8 g of surfactant in 24 ml of oil were used for the smaller emulsion and 1.44 g of surfactant in 24 ml of oil were used for the larger emulsions. For curcumin loaded nano-emulsions, 100 mg of curcumin were added to the 24 ml of oil phase while for piperine loaded nanoemulsions 400 mg of piperine were added to the 24 ml of oil phase. To promote dissolution, the oil phase containing surfactant and biomolecule (curcumin or piperine) was mixed by alternating a high speed blender (RZR 2102 control, Heidolph) at 60 °C and 500 r.p.m. to room temperature sonication with an immersion sonicator (Ultrasonic Processor VCX500 Sonic and Materials), according to a process protocol previously reported [21, 22]. Then, to obtain the pre-emulsion, the oil phase was added dropwise to 90 g of Milli-Q water in the case of the smaller nano-emulsion and to 95 g of Milli-Q water in the case of the larger nano-emulsion and mixed using the immersion sonicator under temperature control in order to avoid overheating. The pre-emulsions were finally passed at 2000 bar through the high-pressure valve homogenizer (Microfluidics M110PS) according to the same previous protocol [21]. Primary emulsions were then coated with pristine chitosan or chitosan 2- iminothiolane conjugate, exploiting their positive charge for the deposition around the oil droplets stabilized with lecithin, which is negative. Chitosan solutions were prepared in 0.1 M acetic acid Milli-Q water bringing the pH to 4 with a small addition of NaOH 6 M solution. The two phases were mixed 1:1 (v:v) quickly under vigorous stirring and kept under stirring for 15 min to allow uniform chitosan deposition, thus obtaining secondary emulsions. The final concentration of oil was 10 wt%, whereas chitosan was 0.1 wt% to guarantee saturation of chitosan around emulsion. The emulsions coated with chitosan were passed through a high-pressure valve homogenizer at 700 bar for 100 continuous steps, and re-processed after a few days in the same conditions on the same systems (at 700 bar for 100 continuous steps) having found benefit in terms of stability by double redispersion process, as previously reported [21]. Emulsions were measured in terms of size and Z-potential (Zetasizer zs nano series ZEN 3600, Malvern Instruments Ltd., Malvern, U.K.) by diluting them up to a droplet concentration of approximately 0.025 wt% using Milli-Q water in the case of primary emulsions and acetic acid solution (pH 4, 20 mM) in the case of secondary emulsions. The Z-potential analysis was carried out by setting 50 runs for each measurement, whereas default refractive index ratio (1.52) and 5 runs for each measurement (1 run lasting 100 s) were used in the calculations of the particle size distribution. Secondary emulsions embedding curcumin and coated with FITC-labelled chitosan were also observed with a SP8-STED fluorescence optical microscope (Leica Microsystems, GmbH, Germany) using a 100X oil immersion objective (HCX PL APO 100x/1.40 OIL). Samples were excited at 488 nm, and the emitted fluorescence was collected between 500 and 550 nm. For image acquisitions in STED mode, a continuous doughnut-shaped STED laser emitting at 592 nm was used. Samples were diluted with a 20 mM acetic acid solution at pH 4 at the final oil concentration of 0.02 wt% and put in glass bottom FD3510 optical dishes. After 30 min of incubation the samples were washed out 3- times with a 5 wt% dabco antifade solution and observed with a microscope. Images were acquired with a pixel\nAC C\nEP TE\nD M\nAN U\nSC R\nIP T\nElsevier\n5\nsize of 25 nm. The full width at half maximum (FWHM), as represented between arrows in the Fig. 2d, and the statistical analysis of the profiles were obtained using Origin 9.1.\nAs control systems -apart from pure curcumin and piperine- we also tested a phytosome formulation. Curcumin and curcumin-piperine phosphatidylcholine complexes were prepared as described in literature [23]. Briefly, the complex was prepared with curcumin and hydrogenated soy phosphatidyl choline (HSPC) at a molar ratio of 1:1. Weighed amount of curcumin and HSPC were put in a 100 ml round bottom flask and 20 ml of dichloromethane was added. The mixture was refluxed at a temperature of maximum 60 °C for 2 h. The obtained solution was evaporated and 10 ml of n-hexane was added under continuous stirring. The curcumin–phospholipid complex was precipitated, subsequently filtered and dried under vacuum to remove traces of solvents. The same procedure was followed for the synthesis of the curcumin-piperine phosphatidylcholine complex.\nAll the tested samples are summarized with their acronyms in Table 1. To represent a particular amount in mg of curcumin per kg of rat, this value will be reported at the end of the identifying code, e.g. NE-CT-110-curc-8 to indicate a formulation based on the 110 nm nano-emulsion coated with chitosan and at a dose of 8 mg of curcumin per kg of rat (corresponding to 7.5 ml of 10 wt% emulsion) will be delivered. Lower doses indicated with 0.8, 0.4 and 0.2 are obtained by administering lower amounts of emulsion (0.75, 0.38 and 0.19 ml/kg, respectively). In the case of piperine co-delivery, piperine is always intended as 1/100 w/w as compared to curcumin amount.\nElsevier 6\nAC C\nEP TE\nD M\nAN U\nSC R\nIP T\nElsevier\n7\n2.5. Cell culture\nMouse fibroblast (NIH/3T3, ATCC® CRL-1658™) and colon cancer cell lines (HT29 ATCC®) were cultured in DMEM and McCoy’s 5A medium, respectively, and both with 2 mM glutamine, 10% FBS1% penicillin streptomycin (full medium) and incubated under standard sterile conditions for cell cultures (5% CO2, 37°C).\n2.6. Cell cytotoxicity experiments\nThe cytotoxicity of the nano-emulsions was assessed on both NIH/3T3 and HT29 evaluating their mitochondrial dehydrogenase activity by means of a modified MTT [3-(4,5-dimethyldiazol-2-yl)-2,5 diphenyltetrazolium bromide] method according to the manufacturer’s instructions (Dojindo Molecular Technologies Inc., Rockville, MD). Cells were seeded in 96-well plates at a density of 10000 cells per well in complete medium at 37 °C in a humidified 5% CO2 atmosphere. After 24 h of appropriate growth, we tested viability of both cell lines incubated one day, under standard conditions, with unformulated curcumin and different types of formulations summarized in Table 1. Curcumin concentration was tested from 2 up to 100 µg/ml in all the cases; the weight ratio between curcumin and piperine was fixed at 100/1 w/w. At the end of the incubation period, cells were washed three times with PBS at pH 7.4 and incubated with 100 μl of a MTT solution (0.5 mg/ml in cell culture medium) for 4 h at 37 °C. The absorbance measurements were acquired at a wavelength of 450 nm with the Tecan Infinite M200 plate-reader using I-control software. The relative cell viability (%) was calculated by the formula [A]test/[A]control×100, where “[A]test” is the absorbance of the test sample, and “[A]control” is the absorbance of the control cells incubated solely with culture medium. After evaluating cell cytotoxicity, the total protein content was measured by using the Micro BCA protein assay kit (Pierce). Briefly, cells were washed with icecold PBS, and incubated for 15 min in 150 μl cell lysis buffer (0.5% v/v Triton X-100 in PBS), to which 150 μl of Micro BCA protein assay kit reagent (prepared following the instructions of the manufacturer) were added. The absorbance at 562 nm was finally measured on a plate reader. The cytotoxicity measurements were then normalized by the amount of total protein content in each well.\n2.7. Cancer cell uptake studies: uptake quantification and cell-imaging by Confocal Laser Scanning\nMicroscope\nFor uptake quantification studies in colon cancer cells, after culturing HT29 cell line as previously described, 5x10 3 cells/well were seeded in 24-well plate and allowed to grow for 24 h. The medium was then replaced with 500 µl of a solution composed by culture medium and the 110 nm nano-emulsion coated with FITC-labelled chitosan (NE-FITC-CT-110-curc), with an equivalent curcumin volume concentration of 1 µg/ml and incubating them for a time comprised between 0.5 and 24 h. Cells were then washed twice with PBS (pH 7.4) and after specified time intervals the experiments were terminated by removing the supernatant, washing the cells three times with 10 mM PBS and lysing them with 0.1 ml of 0.5% Triton X-100 in 0.2 N NaOH. The membrane-bound and internalized nano-emulsions were quantified by analyzing the fluorescence of the cell lysate (λexc = 492 nm,\nAC C\nEP TE\nD M\nAN U\nSC R\nIP T\nElsevier 8\nλem = 528 nm), employing a calibration with a solution composed of NE-FITC-CT-110-curc dispersed in a cell lysate solution (10 6 untreated cells dissolved in 1 ml of the Triton X-100/0.2 N NaOH solution) at final curcumin concentrations ranging from 1.8 µg/ml up to 0.037 ng/ml.\nFor cell imaging studies in colon cancer cells, after culturing HT29 cell line, as previously described, cells were washed with PBS twice (pH 7.4) and membrane was stained by using concanavalin A tetramethylrhodamine conjugate (Invitrogen, Life Technology) at a final concentration of 100 μg/ml. Subsequently, cells were thoroughly rinsed three times with PBS and fixed with a 2.5% glutaraldehyde in PBS for 20 min. Then, cells were blocked with 1% BSA in PBS for 20 min and washed three times with PBS. Finally, they were observed using a Confocal Microscope (C1 Nikon) equipped with an EZ-C1 Software for data acquisition and 60x oil immersion objective. The nanostructures were imaged through excitation/emission of FITC at 4920/528 nm while the cell membrane with excitation/emission at 555/580 nm.\n2.8. Pharmacokinetic studies\nForty-five male Wistar albino rats (mean weight: 400 g) were purchased from Charles River (Calco, Italy) and kept under a 12 h light/dark cycle on standard lab chow. All animals were maintained within conditions specified in approved Institutional Animal Care and Use Committee protocols. The experiment protocol had been previously approved by the local ethics committee. After overnight fasting, animals were randomized in 15 groups (n=3) based on oral administration of unformulated curcumin and the formulations loaded with curcumin or piperine previously listed in Table 1. For all the systems, the volume administered to the rats was 7.5 ml for the entire experiment; when using piperine, weight ratio between curcumin and piperine was 100/1 w/w, as from literature [24]. We chose to work with such high doses to allow the reading of free curcumin in the blood in all the systems including the less performing that is the unformulated curcumin.\nFor each formulation we took, in triplicate, 0.2 ml of blood from rat at each time point (15, 30, 60 and 120 min after oral administration) for a final volume of blood drawn of 0.8 ml, that is <1% of total blood volume (TBV) of a rat weighing 400 g (according to the Veterinary Recommendations for Multiple Blood Draws). Blood was collected by withdrawal via the tail vein into heparinised tubes, centrifuged at 7,000 g for 15 min and plasma was then decanted. Curcumin and curcumin metabolites (glucuronide and sulphate) were extracted from plasma by solid phase extraction; specifically, 0.2 ml of plasma were loaded onto a 0.2 cc Oasis HLB cartridge and washed with 0.2 ml of a solution of methanol: water: glacial acetic acid at 25:25:1 v/v ratio and eluted with 0.2 ml of methanol containing 2% (v/v) of glacial acetic acid. Eluent was evaporated to dryness at 45 °C under nitrogen, and the residue was re-suspended in a 75 µl of 50% v/v water/ acetonitrile solution. Studies of AUC 0-120 min of curcumin and curcumin metabolites were performed only up to 2 h guided by similar works in literature [25]. The relative oral bioavailability of curcumin was calculated according to the equation: Relative BA (%) = 100 x [(AUCformulation/doseformulation) / (AUCunformulated curcumin/doseunformulated curcumin)] as described in literature.\nAC C\nEP TE\nD M\nAN U\nSC R\nIP T\nElsevier\n9\n2.9. Biodistribution studies\nBiodistribution study was performed according to literature [26]; briefly, thirty-six male Wistar albino rats (average weight: 400 g) also purchased from Charles River (Calco, Italy), were housed in temperature and humidity-controlled rooms and allowed free access to basal diet and water ad lib for 7 d before starting the experiment. Rats were randomly divided into 4 groups (n=3/group) depending on the different times of digestion after oral administration of fluorescent nano-emulsion (NE-110-FITC), fluorescent 110 nm nano-emulsion coated with chitosan (NE-CT-110-FITC) and fluorescent 110 nm nano-emulsion coated with chitosan 2-iminothiolane conjugate at a high degree of modification (NE-CT-IT-h-110-FITC): 0.5 h, 1 h, and 2 h. Loading of FITC in the nano-emulsions was obtained by mixing 4 ml of ethanol solution of FITC (0.75 mg/ml) to the soybean oil during the emulsion preparation and drying the ethanol from the mixture with a mild heating. The final concentration of FITC in the 10 wt% emulsion is 125 µg/ml. A single dose of 7.5 ml of FITC loaded nano-emulsions was administered through oral gavage. Rats in the control group received the same volume of vehicle solution (PBS) only. We selected a rather high dose to increase the likelihood of generating detectable amounts of the fluorescent nano-emulsion in tissues. After proper time of digestion, rats were sacrificed and the harvested tissue samples (small intestine, large intestine, liver, spleen, stomach, heart, lung, kidney) were digested using an aqueous enzyme solution containing 1 g/l proteinase K (Sigma-Aldrich) in 50 mM NH4HCO3 buffer (to maintain a constant pH value of 7.4 during enzymatic digestion) and 5 g/l SDS to improve activity of the enzyme [27]. Specifically, organs were carefully weighed and digested in digestion buffer at a weight ratio of 1:5. The samples were thoroughly vortexed and incubated at 37 °C under continuous stirring in a magnetic stirrer for 4 h. Fluorescence of the samples was measured using a Tecan Infinite M200 plate-reader with I-control software at excitation/emission wavelengths of 420/528 nm. The NE-CT-IT-h-110-FITC concentration was determined based on previously prepared standard calibration curves in each organ separately, obtained by spiking blank organ lysates (prepared as previously described) with serial dilutions of fluorescent nano-emulsions ranging from 0 to 50 mg/ml [28].\n2.10. Anti-inflammatory effects in lipopolysaccharide-exposed rats\nForty-two male Wistar albino rats (mean weight: 400 g) purchased from Charles River (Calco, Italy) were treated as in the biodistribution study before starting the experiment. Rats were randomly divided into 7 groups (n=6/group): control (normal saline), Unformulated curc, NE-CT-IT-h-110-curc-0.8, NE-CT-IT-h-110-curcpiper-0.8. In order to verify the possible concentration dependent effects of the formulations, we subsequently tested the anti-inflammatory effects of: control (normal saline), NE-CT-IT-h-110-curc-piper-0.4, NE-CT-IT-h110-curc-piper-0.2.\nSolutions were administered daily for 2 weeks by oral gavage and, after this period, a single intraperitoneal injection (IP) of LPS at 5 mg/kg was performed. Blood samples were taken just before (= time 0), and at two different times (2, 5 h) after LPS injection under ether anaesthesia- by withdrawal via the tail vein. This timing aimed to obtain the maximum production of pro-inflammatory cytokines after IP administration of LPS in rats, as observed in literature [29, 30]. Blood samples were collected in heparinised tubes and immediately centrifuged at 3000 rpm for 10 min at 4 °C in order to obtain plasma that was collected, frozen, and kept at −80° C until use for\nAC C\nEP TE\nD M\nAN U\nSC R\nIP T\nElsevier 10\nIL-1β, TNF-α, IL-6 and IL-8 analysis performed by enzyme-linked immunosorbent assay (ELISA) method using commercial kits (Bio-Rad Laboratories, Inc., Italy).\n2.11. Statistical analysis\nThe results are represented as mean ± standard error of the mean (SEM). A one-way analysis of variance (ANOVA) followed by post-hoc Fisher's Least Square Difference (LSD) test was used to compare groups. Values of P < 0.05 were considered statistically significant."
    }, {
      "heading" : "3. Results and discussion",
      "text" : "3.1 Nano-emulsions analysis\nParticle size of curcumin loaded nano-emulsions was characterized by DLS. Smaller nano-emulsions coated with\npristine chitosan exhibited a size of 110 nm in diameter and a PDI of 0.09, as depicted in Fig. 1F. However, the use of chitosan 2-iminothiolane conjugate as a coating did not significantly affect the final size and PDI even\nat the highest degree of modification (size 110 nm and PDI 0.1). Then, to study the effects of size on bioavailability, the formulation with a lower amount of lecithin surfactant was also measured by DLS showing a\ncirca double final size (size 230 nm and PDI 0.06). In this work pristine chitosan was modified with FITC and as an example the smaller nano-emulsion containing curcumin was coated with such FITC labeled chitosan to be visualized in fluorescence. In particular, this nano-emulsion was characterized by using a STED microscope (high resolution < 100 nm), since the expected size was around 110 nm. This size measured by DLS was confirmed by STED analysis, as illustrated in Fig. 1A-E, where confocal and STED acquisition are compared. Real size given by the STED image indicates that most of the nano-droplets are about 110 nm large, proving the narrow distribution feature of our secondary nano-emulsions. Statistical analysis confirmed size and monodispersion provided by DLS. In addition, as shown in previous works [21, 31] the process utilized to produce such chitosan coated nano-emulsions allows stability to last longer than 1 year.\nElsevier\n11\nAC C\nEP TE\nD M\nAN U\nSC R\nIP T\nElsevier 12\nThis characterization demonstrates -as already shown by DLS- the capability to dimensionally control our nanocarriers so that all the results can be associated to a specific size. The degrees of functionalization measured by applying the Ellman’s test were 7.2% for the chitosan 2-iminothiolane conjugate at the medium degree of modification (CT-IT-m), 15.1 % for the highest degree of modification (CT-IT-h) in the case of deposition on the larger nano-emulsion size and -finally- 13.6% for the highest degree of modification in the case of deposition on the smaller nano-emulsion. Changes in the structure upon functionalization can be evidenced also by NMR spectra, presented in Fig. S1. Compared to the spectrum of pristine chitosan (in the bottom of the image), it is possible to observe the appearance of new peaks, in particular at 1.76 ppm, 2.30 ppm and 2.42 ppm, associated with the methylene groups of the thio-butyl-amidine (at the top right corner of the figure).\n3.2 Cell cytotoxicity\nWe tested the biosafety of the nano-emulsions and the capability of our nano-emulsion to maintain curcumin activity by carrying out cytotoxicity tests on the different formulations loaded and non-loaded with curcumin and/or piperine always at 1/100 w/w ratio with curcumin (Fig. 2). First of all, cell viability results demonstrated, in 3T3 (Fig. 2A) and HT29 (Fig. 2B) cell lines, the non-toxicity of the different formulations alone indicating the biosafety of the tested carriers. As regards formulated curcumin, against fibroblasts, nano-emulsions loading curcumin alone and in combination to piperine (weight ratio 100:1) did not show a significant toxicity up to 100 µg/ml of corresponding curcumin concentration for incubation times up to 24 h (Fig. 2C,E). Similarly, unformulated piperine and nano-emulsions loaded with piperine (reported in Supplementary material, Fig. S1) showed no significant cytotoxicity against both cell lines. In contrast, formulated curcumin showed high toxicity in the colon cancer cells (HT29 cell line) after 24 h of contact compared to unformulated curcumin (Fig. 2D,F). In addition, at 100 µg/ml as reported in Fig. 2D, NE-CT-IT-110-curc, showed a significant lower level of toxicity compared to NE-CT-IT-h-110-curc (p<0.05). This effect can be explained considering the higher cytoadhesive properties of thiolated polymers due to more interactions with the cellular membrane [32, 33]. According to this concept an IC50 at 65 and at 25 µg/ml, respectively, for NE-CT-IT-m-110-curc and NE-CT-IT-h-110-curc, was observed, indicating a concentration-dependent interaction between the thiol groups on chitosan and the cell membrane. Administration of curcumin and piperine in combination led to a higher level of cytotoxicity, that is statistically significant only when comparing NE-CT-IT-h-110-curc and NE-CT-IT-h-110-curc-piper(p<0.05), as depicted always in Fig. 2D; this behaviour suggests a possible adjuvant action of piperine in the anti-proliferative molecular mechanism of curcumin against human colon cancer cells as also shown in Fig. 2F. On the basis of these results, the best cytotoxic formulation was the NE-CT-IT-h-110-curc-piper, exhibiting an IC50 value at 24 h of 15 µg/ml of curcumin, which was significantly lower than curcumin concentrations needed to reach IC50 by the other formulations (in the case of unformulated curcumin IC50 was not reached at all). Interestingly, comparing results on both cell lines, we observed pronounced toxicity of curcumin against human colon cancer cells in agreement with recent literature sources reporting selective anticancer properties of this molecule alone [34], or in combination with conventional anticancer drugs [35-37]. These results prove that the selective action property of curcumin is maintained when encapsulated in our nano-emulsions.\nAC C\nEP TE\nD M\nAN U\nSC R\nIP T\nElsevier\n13\nFig. 2: Viability of 3T3 (A, C, E) and HT29 (B, D, F) cells after 24 h of exposure at 37 °C as a function of nanoemulsion (mg oil/ml) and curcumin (µg/ml) concentration. *p<0.01; **p<0.05; ns: not significant.\n3.3 Cancer cell imaging and internalization studies\nFollowing FITC emission, a cell uptake study was carried out, Fig. 3. For this analysis we used the 110 nm curcumin nano-emulsion coated with FITC-labelled chitosan, NE-FITC-CT-110-curc at a correspondent curcumin volume concentration of 1 µg/ml. The graph presented in Fig. 3 (up) corresponds to the amount of internalized nano-emulsions (expressed as µg of chitosan /mg of proteins), plus cell surface-bound nanoemulsions. NE-FITC-CT-110-curc were taken up very rapidly by HT29 cell line, with a value of 150 µg of corresponding chitosan per mg cell protein reached after as early as 4 h of incubation; other literature reports confirm the rapidity of cellular uptake due to electrostatic interactions between the cellular membrane and the positively charged chitosan [38]. Confocal images show that NE-FITC-CT-110-curc (green in Fig. 3) was visibly\n** * n.s\n** **\nAC C\nEP TE\nD M\nAN U\nSC R\nIP T\nElsevier 14\nassociated to peripheral intracellular compartments at early time points (0.5-4 h, Fig. 3A-C), whereas a more central localization was recorded after 24 h (Fig. 3D). These results demonstrate the nano-emulsion uptake ability and the time dependent internalization in human colon cancer cells with a tendency to accumulate in the perinuclear regions of the cells after 24 h, which is generally advantageous for drugs that intercalate with DNA - such as curcumin.\nFig. 3 Up: Overall cellular uptake quantification of NE-FITC-CT-110-curcat a corresponding curcumin concentration of 1 µg/ml internalized in colon cancer cells (HT29 cell line) as a function of time. Down: Confocal Laser Scanning Microscope images of colon cancer cells (HT29 cell line), after 0.5 (A), 2 (B), 4 (C) and 24 h (D) of contact with NE-FITC-CT-110-curc at a corresponding curcumin concentration of 1 µg/ml; the green punctuated fluorescence corresponds to uptaken nano-emulsion, which clearly moves from a peripheral to a central (perinuclear) localization during the incubation time. Green signal: FITC; Red signal: Concanavalin A Tetramethylrhodamine conjugate. Scale bar: 50 µm.\nAC C\nEP TE\nD M\nAN U\nSC R\nIP T\nElsevier\n15\n3.4 Pharmacokinetic studies\nPharmacokinetic data related to 8 mg/kg doses are reported in Table 2 and Fig. 4. They include data related to absolute curcumin AUC, curcumin Cmax, curcumin AUC ratio with its two main metabolites and relative curcumin bioavailability (%). As shown, compared to unformulated curcumin, orally administered nanoemulsions loaded with curcumin always determined an increase in both maximum concentration (Cmax) and AUC of the curcumin and its two metabolites, glucoronidated and sulphated; thus, formulated curcumin led to a greater intestinal drug adsorption capacity than unformulated curcumin, with a consequent increase in its metabolized forms. For example, the relative bioavailability of NE-CT-IT-h-110-curc-piper-8 was 64 times higher than that of Unformulated curc-8. In relation to the different nano-emulsion parameters, the presence of thiols on chitosan 2- iminothiolane conjugate demonstrated a central role in increasing curcumin AUC after oral administration in rats; the beneficial effects of piperine co-delivery, are also evident as well as the role of the size, whose scaling was fundamental to strongly gain in curcumin AUC.\nIn particular, all the results summarized in Fig. 4 and Table 2 confirm the essential role of piperine in the pharmacokinetic profile of curcumin, in agreement with previous works related to the co-administration of unformulated curcumin and piperine [11, 39]. In fact, as reported in Fig. 4, which describes the ratios of metabolites (glucuronide, C and sulphate, E) to parent curcumin AUCs, the presence of piperine determined beneficial changes in curcumin metabolism with the various treatments.\nIn addition, with respect to the effect of chitosan modification, as reported in Table 2 and Fig. 4, focusing on the cases of piperine co-delivery, oral administration of NE-CT-110-curc-piper-8, NE-CT-IT-m-110-curc-piper-8 and NE-CT-IT-h-110-curc-piper-8, compared to Unformulated curc-8, increased AUC of curcumin 9.2, 22 and 63.6 times, respectively. These data indicate the important role of the degree of chitosan modification with 2- iminothiolane in the phenomena of uptake and intestinal absorption after oral administration in rats.\nFinally, from Table 2 and Fig. 4 it is also possible to make a comparison in terms of size. Specifically, NE-CTIT-h-220-curc-piper-8 increased curcumin AUC 23.4 times compared to Unformulated curc-8 but, very interestingly curcumin AUC value was drastically lower than curcumin AUC provided by NE-CT-IT-h-110-curcpiper-8 (2.11 ±0.18 vs. 5.73 ± 0.61; p<0.001), indicating the essential role of the size of the nano-emulsion in the phenomena of uptake and intestinal absorption after oral administration in rats.\nFor completeness, we also performed a comparison with a more traditional lipid formulation based on a curcumin phosphatidylcholine complexation under the same conditions of dilution; our best nano-emulsion showed a significant improvement in curcumin bioavailability, as reported in Table 2 and Fig. 4A. For example, NE-CTIT-h-110-curc-piper-8 increased curcumin AUC 4 times compared to curcumin-piperine phosphatidylcholine complexation (5.73 ± 0.61 vs. 1.44 ± 0.22) in a statistically significant manner (p<0.001)\nIn conclusion, on the basis of these pharmacokinetic data, co-administering curcumin and piperine in stabilized lipid 110 nm nano-emulsions and coated with chitosan 2-iminothiolane conjugate at the highest degree of modification, we achieved, compared to other pharmacokinetic studies after oral administration in rats, a 6-fold increase in curcumin AUC compared to the most recent nano-emulsion systems [13], and a 1.6-fold increase compared to the best performing system so far reported [14].\nAC C\nEP TE\nD M\nAN U\nSC R\nIP T\nElsevier 16\nVery interestingly, from an applicative point of view, even administering 0.8, 0.4 or 0.2 mg/kg of corresponding curcumin concentration of CT-IT-h-110-curc-piper, we continued to see detectable amount of curcumin and its metabolites as shown in Table 3 and Fig. 5 and the difference between concentrations was always statistically significant.\nFormulations (8 mg/kg of curcumin) Parameters Curcumin Curcumin glucoronide\nCurcumin sulphate\nCmax (nM) 0.12 ± 0.04 4.5 ± 0.25 0.21 ± 0.18 Unformulated curc Tmax (min) 30 30 60 AUC (µg min/ml) 0.09 ± 0.03 3.7 ± 0.1 0.34 ± 0.11 Relative bioavailability (%) 1 Cmax (nM) 0.28 ± 0.19 68.7± 5.4 0.48 ± 0.25 NE curc Tmax (min) 15 30 60 AUC (µg min/ml) 0.27 ± 0.07 71.4 ± 8.6 0.38 ± 0.08 Relative bioavailability (%) 3 ± 0.1 Cmax (nM) 0.69 ± 0.47 112.5 ± 2.5 0.84 ± 0.56 NE-CT-110-curc Tmax (min) 15 30 60 AUC (µg min/ml) 0.52 ± 0.13 121.8 ± 7.3 0.93 ± 0.17 Relative bioavailability (%) 5.7 ± 0-8 Cmax (nM) 1.05 ± 0.32 88.7 ± 1.8 0.9 ± 0.33 NE-CT-110-curc-piper Tmax (min) 15 30 60 AUC (µg min/ml) 0.83 ± 0.18 81.1 ± 4.3 0.98 ± 0.12 Relative bioavailability (%) 9.2 ± 1.5 Cmax (nM) 1.69 ± 0.5 201.5 ± 2.4 0.82 ± 0.2 NE-CT-IT-m-110-curc Tmax (min) 15 30 60 AUC (µg min/ml) 1.86 ± 0.21 211.8 ± 13.3 1.21 ± 0.3 Relative bioavailability (%) 9.5 ± 1.1 Cmax (nM) 2.78 ± 0.31 101.8 ± 3.1 0.98 ± 0.83 NE-CT-IT-m-110-curc-piper Tmax (min) 15 30 60 AUC (µg min/ml) 1.98 ± 0.34 118.3 ± 15.6 0.63 ± 0.3 Relative bioavailability (%) 22 ± 2.8 Cmax (nM) 2.07 ± 0.21 341.1 ± 1.7 1.14 ± 0.4 NE-CT-IT-h-110-curc Tmax (min) 15 30 60 AUC (µg min/ml) 2.99 ± 0.55 316.2 ± 18.3 2.09 ± 0.22 Relative bioavailability (%) 33.2 ± 2.7 Cmax (nM) 3.98 ± 0.13 153.4 ± 2.6 1.28 ± 0.61 NE-CT-IT-h-110-curc-piper Tmax (min) 15 30 60 AUC (µg min/ml) 5.73 ± 0.61 156.7 ± 17.2 1.47 ± 0.13 Relative bioavailability (%) 64 ± 4.3 Cmax (nM) 1.07 ± 0.18 172.1 ± 2.3 0.96 ± 0.9 NE-CT-IT-h-220-curc Tmax (min) 15 30 60 AUC (µg min/ml) 1.19 ± 0.15 216.4 ± 11.2 2.09 ± 0.3 Relative bioavailability (%) 13.2 ± 1.2 Cmax (nM) 2.18 ± 0.23 1.07 ± 1.9 0.88 ± 0.31 NE-CT-IT-h-220-curc-piper Tmax (min) 15 30 60 AUC (µg min/ml) 2.11 ± 0.18 102.7 ± 16.2 0.97 ± 0.12 Relative bioavailability (%) 23.4 ± 1.9 Cmax (nM) 0.61 ± 0.21 121.4 ± 5.2 0.93 ± 0.46 Phosphatidylcholine based formulation of curc Tmax (min) 15 30 60 AUC (µg min/ml) 0.85 ± 0.18 163.8 ± 17.3 0.66 ± 0.13 Relative bioavailability (%) 9.4 ± 0.5 Cmax (nM) 1.06 ± 0.42 82.8 ± 4.3 0.91 ± 0.49 Phosphatidylcholine based formulation of curc-piper Tmax (min) 15 30 60 AUC (µg min/ml) 1.44 ± 0.22 89.9 ± 11.8 0.59 ± 0.1 Relative bioavailability (%) 16 ± 1.3\nTable 2: Calculated nanomolar plasma peak levels (Cmax), time of peak levels (Tmax), AUC expressed as µg min /ml and relative bioavailability (%).\nAC C\nEP TE\nD\nM\nAN\nU\nSC R\nIP T\nElsevier\n17\nFormulations Parameters Curcumin Curcumin glucoronide\nCurcumin sulphate\nCmax (nM) 3.98 ± 0.13 153.4 ± 2.6 1.28 ± 0.61 NE-CT-IT-h-110-curc-piper (8 mg/kg of curcumin) Tmax (min) 15 30 60 AUC (µg min/ml) 5.73 ± 0.61 156.7 ± 17.2 1.47 ± 0.13 Cmax (nM) 0.65 ± 0.09 24.8 ± 1.2 0.21 ± 0.1 NE-CT-IT-h-110-curc-piper (0.8 mg/kg of curcumin) Tmax (min) 15 30 60 AUC (µg min/ml) 0.85 ± 0.12 25,7 ± 2.8 0.26 ± 0.02 Cmax (nM) 0.36 ± 0.07 13.6 ± 0.9 0.13 ± 0.2 NE-CT-IT-h-110-curc-piper (0.4 mg/kg of curcumin) Tmax (min) 15 30 60 AUC (µg min/ml) 0.51 ± 0.11 14.2 ± 1.5 0.14 ± 0.03 Cmax (nM) 0.2 ± 0.06 7.2 ± 0.5 0.09 ± 0.05 NE-CT-IT-h-110-curc-piper (0.2 mg/kg of curcumin) Tmax (min) 15 30 60 AUC (µg min/ml) 0.22 ± 0.05 6.8 ± 0.9 0.09 ± 0.01\nTable 3: Calculated nanomolar plasma peak levels (Cmax), time of peak levels (Tmax) and Area Under Curve (AUC) expressed as µg min/ml for NE-CT-IT-h-110-curc-piper at 0.8, 0.4 and 0.2 mg/kg of corresponding curcumin concentration.\nAC C\nEP TE\nD M\nAN U\nSC R\nIP T\nElsevier 18\nAC C\nEP TE\nD\nM\nAN U\nSC R\nIP\nT\nElsevier\n19\nFig. 4: Curcumin AUC (A) AUC ratio between curcumin and curcumin glucuronide and sulphate (B, C) and relative bioavailability (%) comparison (D) between unformulated curcumin and nano-emulsions at 8 mg/kg orally administered in rats. *p<0.01; **p<0.001; ***p<0.05; ns: not significant.\nFig. 5: Curcumin AUC comparison between unformulated curcumin and nano-emulsions at 8, 0.8, 0.4, 0.2 mg/kg orally administered in rats. *p<0.01; **p<0.001; ***p<0.05; ns: not significant.\n3.5 Biodistribution studies\nWe evaluated the biodistribution of different fluorescent nano-emulsions, such as NE-FITC, NE-CT-110-FITC and NE-CT-IT-h-110-FITC, from the gastrointestinal tract to different organs within 2 h after a single oral administration in rats. Accumulation of nano-emulsions in different organs expressed as % of the injected dose is shown in Fig. 6. All tested nano-emulsions induced a significant increase in fluorescence in at least one of the tested organs, as expected in the case of passage through the intestinal wall. In the stomach there was a time dependent decrease in fluorescence related to all formulations with a very low percentage of the injected dose 2 h after oral administration; conversely, we observed a time dependent increase in fluorescence in the liver and spleen with higher levels of accumulation achieved 2 h after oral administration. The general high fluorescence intensity in liver can be justified by the presence of the reticuloendothelial system (RES); in fact, oral delivery along its path unavoidably encounters liver parenchyma where hepatocytes and liver macrophages (Kupffer cells) are able to recognize and metabolize nanocarriers; the same happens at the spleen level [40]. In this context, the co-delivery of piperine was helpful since it could inhibit some enzymatic activities of curcumin useful for its bioavailability, as demonstrated in the pharmacokinetic study. Interestingly, in the small intestine (after 1 h of administration) and liver (after 2 h of administration) the percentage of the injected dose of NE-CT-IT-h-110FITC was significantly higher than that of the NE-CT-110-FITC (p<0.01 for both organs) and NE-110-FITC (p<0.005, p<0.01 for small intestine and liver, respectively). Specifically, the percentage of the injected dose of NE-CT-IT-h-110-FITC was more than 3 times higher, at 1 h after administration, compared to NE-110-FITC and\nR\nIP T\nElsevier 20\n1.5 times compared to NE-CT-110-FITC (p<0.01) in agreement with a supposed improved passage through the intestinal barrier deriving from the higher mucoadhesive ability of nano-emulsions determined by the presence of chitosan and especially of modified chitosan (Fig. 6A-C). Conversely, NE-110-FITC seemed to accumulate more in the large intestine compared to the others (p<0.001) indicating, probably, a worse mucoadhesive ability in the small intestine. Future experiments are under investigation for the use of 14 C-labelled curcumin in order to follow more closely the destiny of the drug.\n3.6 Anti-inflammatory effects in lipopolysaccharide-exposed rats\nMany cytokines and interleukines have been reported to act as anti or pro-inflammatory factors; it has been recently found that these are produced also by cancer cells, or by the tumor microenvironment, in order to develop their progression and survival [41, 42]. In this study, we focused our attention on four molecules, tumor\nAC C\nEP TE\nD M\nAN U\nSC R\nIP T\nElsevier\n21\nnecrosis factor (TNF-α), interleukin (IL)-1β, IL-8 and IL-6. TNF-α is an extremely potent autocrine and paracrine mediator of inflammation and several studies demonstrated its over expression in cancer tissue and carcinoma cell lines [43]. Il-1 β is another essential pro inflammatory cytokine that plays a regulatory role in the growth of cancer cells also by autocrine mechanisms [44]; IL-8 a is a pro-inflammatory cytokine with a key role in the initiation and amplification of acute inflammatory reactions [45] and regulation of tumor cell growth and metastasis of thyroid, colon and breast cancer. IL-6 is a cytokine whose hypersecretion by tumor microenvironment induces proliferation and a more aggressive phenotype, for example, in ER-positive breast cancer cells [46]; it is also well known that an increased IL-6 expression is related to an advanced stage of disease and decreased survival in colorectal cancer patients [47].\nOn the basis of the emerging key role of cytokines in tumor growth and survival, a potential modulation of the plasma concentration of these cytokines also under pro-inflammatory conditions could be crucial. The above mentioned pro-inflammatory cytokines (TNF-α, IL-1β, IL-8 and IL-6) were produced in this study upon LPS injection in vivo. These cytokines were used, both in cellular and animal studies, as mediators of molecules present in the outer membranes of Gram-negative bacteria [30, 48]. As shown in Fig. 7, interleukin plasma concentration increased exponentially by two (IL-1β, IL-8) and three (IL-6) orders over 5 h upon LPS injection in rats (point 0) with a mean value of 356.6 ± 11.1, 455.3 ± 19.2 and 853.8 ± 14.5 pg/ml, respectively. Instead, TNF-α levels showed a sharp plasmatic increase by two orders over 2 h upon LPS administration with a successive plateau phase with a mean concentration of 788.5 ± 7.3 pg/ml after 5 h. The increase in plasma concentration of the analysed interleukins is in agreement with literature [49], and is mainly related to the TLR4 receptor stimulation by LPS with subsequent induction of cytokines and interleukine production [50].\nOral pre-administration of Unformulated curc-0.8 did not show any statistically significant changes in cytokine levels in plasma, demonstrating no significant anti-inflammatory activity (Fig. 7). Conversely, oral preadministration of NE-CT-IT-h-110-curc-0.8 reduced the magnitude of the increase in plasma IL-1β, IL-8, IL-6 and TNF-α levels; specifically, the treatment reduced approximately by 40% (213 ± 9 vs. 356 ± 11), 25% (588 ± 11 vs. 788 ± 7), 26% (632 ± 22 vs. 853 ± 14) and 24% (346 ± 25 vs. 455 ± 19) the production of IL-1β, TNF-α, IL-6, IL-8, respectively, compared to the control group (p < 0.005), (Fig. 7). In the presence of piperine codelivery, NE-CT-IT-h-110-curc-piper-0.8 reduced the magnitude of the increase in plasma IL-1β, IL-8, IL-6 and TNF-α levels in an even more significant manner indicating the adjuvant effect of the alkaloid piperine; specifically, it reduced approximately by 57% (153 ± 13 vs. 356 ± 11), 48% (406 ± 15 vs. 788 ± 7), 51% (416 ± 18 vs. 853 ± 14) and 60% (181 ± 15 vs. 455 ± 19) the production of IL-1β, TNF-α, IL-6, IL-8, respectively, compared to the control group (P < 0.001), (Fig. 7).\nThese data indicate that even at a 1/10 dose (=0.75 ml/kg), the best formulation coming from the pharmacokinetic study, NE-CT-IT-h-110-curc-piper, has an effective anti-inflammatory action when orally administered to LPS treated rats.\nMoreover, we tested the anti-inflammatory effect of two lower doses, such as NE-CT-IT-H-110-curc-piper-0.4 and of NE-CT-IT-H-110-curc-piper-0.2. As it is possible to see from Fig. 8, in both cases a relevant reduction of IL-1β, TNF-α, IL-6, IL-8, as compared to the control groups (P < 0.01) was obtained. Specifically, the first dose (0.4 mg/kg) reduced by approximately 37% (253 ± 15 vs. 402 ± 22), 30% (582 ± 23 vs. 821 ± 31), 32% (628 ± 33 vs. 921 ± 28) and 39% (293 ± 23 vs. 478 ± 11) the production of IL-1β, TNF-α, IL-6, IL-8, respectively, compared to the control group (P < 0.01). The second dose (0.2 mg/kg) reduced by approximately 25% (301 ± 14\nAC\nC\nEP TE\nD M\nAN U\nSC R\nIP T\nElsevier 22\nvs. 402 ± 22), 14% (702 ± 26 vs. 821 ± 31), 19% (745 ± 27 vs. 921 ± 28) and 14% (407 ± 17 vs. 478 ± 11) the production of IL-1β, TNF-α, IL-6, IL-8, respectively, compared to the control group (P < 0.01).\nFig. 7: Effects of Unformulated curc-8, NE-CT-IT-h-110-curc-8 and NE-CT-IT-h-110-curc-piper-8 on plasma cytokine levels-time profiles in lipopolysaccharide-exposed rats. The levels of plasma cytokines were measured before and after 2 and 5 h the LPS intraperitoneal injection in rats pre-treated with normal saline solution (Control) and Unformulated curc at 0.8 mg/kg; NE-CT-IT-h-110-curc at the same curcumin dose of 0.8 mg/kg; NE-CT-IT-h-110-curc, at the same curcumin dose of 0.8 mg/kg and piperine 0.01 mg/kg. * p < 0.001. ** p<0.05.\nAC C\nEP\nTE\nD\nM\nAN U\nSC R\nIP T\nElsevier\n23\nFig. 8: Concentration dependent anti-inflammatory effects of NE-CT-IT-h-110-curc-piper-0.8; NE-CT-IT-h-110curc-piper-0.4 and NE-CT-IT-h-110-curc-piper-0.2 in lipopolysaccharide-exposed rats. The levels of plasma cytokines were measured just before and after 2 and 5 h from the LPS intraperitoneal injection. *p<0.05; **p<0.01; ***p<0.001"
    }, {
      "heading" : "4. Conclusions",
      "text" : "The oral route remains the easiest way to effectively deliver natural substances, such as nutraceuticals. In this work we used a modular system to convey curcumin based on a food grade nano-emulsion; the system is capable of controlling the interface properties and therefore the interaction with the intestinal barrier by easy deposition of functionalized biopolymers. In particular, we studied curcumin bioavailability by using chitosan with different degrees of modification with 2-iminothiolane, the effects of the nano-emulsion size by comparing 110 nm and 230 nm emulsions and the effects of piperine co-delivery, which has been already reported to enhance curcumin bioavailability. We obtained the highest degree of bioavailability in the case of the smaller nano-emulsion coated with the highest degree of chitosan modification with 2-iminothiolane and co-delivery of piperine. Apart from elucidating the roles played by the different parameters in a systematic way, we obtained a relative bioavailability of NE-CT-IT-h-110-curc-piper which was 64 times higher than unformulated curcumin, the highest ever reached. In addition, we propose a modular system which may add complexity by exploiting its capability to further deposit layers and provide multi-compartmentality and therefore multifunctionality. Then, we showed very high anti-inflammatory activities based on the reduction of IL-1β, TNF-α, IL-6 and IL-8 in LPS treated rats at 0.8 mg of curcumin per kg of rat (corresponding to 0.75 ml/kg of rat) and even significant at doses as low as 0.2 mg of curcumin per kg of rat (corresponding to 0.19 ml/kg of rat). Given the anti-inflammatory and also chemopreventive power of curcumin, we have planned clinical trials in the care of the inflammatory bowel\nAC C\nEP TE\nD M\nAN U\nSC R\nIP T\nElsevier 24\ndisease (IBD) and in chemoprevention of the colorectal cancer. Moreover, based on the selective action of the curcumin against cancer cells as proved in literature, we demonstrated that this property is maintained when curcumin is encapsulated in our systems. Studies of combinatory treatments of chemotherapy drugs and curcumin, both orally administered, exploiting their pharmacological synergism and chemosensitization in different cancer types are currently under investigation."
    }, {
      "heading" : "Acknowledgments",
      "text" : "The authors thank the animal facility of Federico II University of Naples for providing rats, Vittoria Berardinone for the preparation of some emulsions and Roberta Infranca for the precious proofreading."
    } ],
    "references" : [ {
      "title" : "Curcumin: the Indian solid gold",
      "author" : [ "B.B. Aggarwal", "C. Sundaram", "N. Malani", "H. Ichikawa" ],
      "venue" : "in: The molecular targets and therapeutic uses of curcumin in health and disease, Springer",
      "citeRegEx" : "1",
      "shortCiteRegEx" : null,
      "year" : 2007
    }, {
      "title" : "Effect of pure curcumin",
      "author" : [ "S. Anuchapreeda", "S. Tima", "C. Duangrat", "P. Limtrakul" ],
      "venue" : "demethoxycurcumin, and bisdemethoxycurcumin on WT1 gene expression in leukemic cell lines, Cancer chemotherapy and pharmacology, 62 ",
      "citeRegEx" : "2",
      "shortCiteRegEx" : null,
      "year" : 2008
    }, {
      "title" : "Role of curcumin as a subgingival irrigant: A pilot study",
      "author" : [ "A. Suhag", "J. Dixit", "P. Dhan" ],
      "venue" : "Perio, 4 ",
      "citeRegEx" : "3",
      "shortCiteRegEx" : null,
      "year" : 2007
    }, {
      "title" : "Curcumin: getting back to the roots",
      "author" : [ "S. Shishodia", "G. Sethi", "B.B. Aggarwal" ],
      "venue" : "Annals of the New York Academy of Sciences, 1056 ",
      "citeRegEx" : "4",
      "shortCiteRegEx" : null,
      "year" : 2005
    }, {
      "title" : "Bioavailability of curcumin: problems and promises",
      "author" : [ "P. Anand", "A.B. Kunnumakkara", "R.A. Newman", "B.B. Aggarwal" ],
      "venue" : "Molecular pharmaceutics, 4 ",
      "citeRegEx" : "5",
      "shortCiteRegEx" : null,
      "year" : 2007
    }, {
      "title" : "Potential role of curcumin phytosome (Meriva) in controlling the evolution of diabetic microangiopathy",
      "author" : [ "G. Appendino", "G. Belcaro", "U. Cornelli", "R. Luzzi", "S. Togni", "M. Dugall", "M. Cesarone", "B. Feragalli", "E. Ippolito", "B. Errichi" ],
      "venue" : "A pilot study, Panminerva Med, 53 ",
      "citeRegEx" : "6",
      "shortCiteRegEx" : null,
      "year" : 2011
    }, {
      "title" : "Water soluble complexes of curcumin with cyclodextrins: Characterization by FT-Raman spectroscopy",
      "author" : [ "P.K. Mohan", "G. Sreelakshmi", "C. Muraleedharan", "R. Joseph" ],
      "venue" : "Vibrational Spectroscopy, 62 ",
      "citeRegEx" : "7",
      "shortCiteRegEx" : null,
      "year" : 2012
    }, {
      "title" : "A pilot cross-over study to evaluate human oral bioavailability of BCM-95® CG (BiocurcumaxTM)",
      "author" : [ "B. Antony", "B. Merina", "V. Iyer", "N. Judy", "K. Lennertz", "S. Joyal" ],
      "venue" : "a novel bioenhanced preparation of curcumin, Indian journal of pharmaceutical sciences, 70 ",
      "citeRegEx" : "8",
      "shortCiteRegEx" : null,
      "year" : 2008
    }, {
      "title" : "Dietary fish oil and curcumin combine to modulate colonic cytokinetics and gene expression in dextran sodium sulphate-treated mice",
      "author" : [ "Q. Jia", "I. Ivanov", "Z.Z. Zlatev", "R.C. Alaniz", "B.R. Weeks", "E.S. Callaway", "J.S. Goldsby", "L.A. Davidson", "Y.-Y. Fan", "L. Zhou" ],
      "venue" : "British journal of nutrition, 106 ",
      "citeRegEx" : "9",
      "shortCiteRegEx" : null,
      "year" : 2011
    }, {
      "title" : "Isolation of piperine from black pepper",
      "author" : [ "W.W. Epstein", "D.F. Netz", "J.L. Seidel" ],
      "venue" : "Journal of chemical education, 70 ",
      "citeRegEx" : "10",
      "shortCiteRegEx" : null,
      "year" : 1993
    }, {
      "title" : "Influence of Piperine on the Pharmacokinetics of Curcumin in Animals and Human Volunteers",
      "author" : [ "G. Shoba", "D. Joy", "T. Joseph", "M. Majeed", "R. Rajendran", "P.S.S.R. Srinivas" ],
      "venue" : "Planta Med, 64 ",
      "citeRegEx" : "11",
      "shortCiteRegEx" : null,
      "year" : 1998
    }, {
      "title" : "Enhancing anti-inflammation activity of curcumin through O/W nanoemulsions",
      "author" : [ "X. Wang", "Y. Jiang", "Y.-W. Wang", "M.-T. Huang", "C.-T. Ho", "Q. Huang" ],
      "venue" : "Food Chemistry, 108 ",
      "citeRegEx" : "12",
      "shortCiteRegEx" : null,
      "year" : 2008
    }, {
      "title" : "Enhancement of curcumin oral absorption and pharmacokinetics of curcuminoids and curcumin metabolites in mice",
      "author" : [ "L. Zhongfa", "M. Chiu", "J. Wang", "W. Chen", "W. Yen", "P. Fan-Havard", "L.D. Yee", "K.K. Chan" ],
      "venue" : "Cancer chemotherapy and pharmacology, 69 ",
      "citeRegEx" : "13",
      "shortCiteRegEx" : null,
      "year" : 2012
    }, {
      "title" : "Innovative preparation of curcumin for improved oral bioavailability",
      "author" : [ "H. Sasaki", "Y. Sunagawa", "K. Takahashi", "A. Imaizumi", "H. Fukuda", "T. Hashimoto", "H. Wada", "Y. Katanasaka", "H. Kakeya", "M. Fujita" ],
      "venue" : "Biological and Pharmaceutical Bulletin, 34 ",
      "citeRegEx" : "14",
      "shortCiteRegEx" : null,
      "year" : 2011
    }, {
      "title" : "Chitosan—A versatile semi-synthetic polymer in biomedical applications",
      "author" : [ "M. Dash", "F. Chiellini", "R.M. Ottenbrite", "E. Chiellini" ],
      "venue" : "Progress in polymer science, 36 ",
      "citeRegEx" : "15",
      "shortCiteRegEx" : null,
      "year" : 2011
    }, {
      "title" : "Thiolated chitosan: a novel mucoadhesive polymer: a review",
      "author" : [ "Vijapur.L.S", "S.S.A", "Patil.S.H", "Vijapur.P.V", "Patwari.P.K", "Saraswathi" ],
      "venue" : "International Research Journal of Pharmacy,",
      "citeRegEx" : "16",
      "shortCiteRegEx" : "16",
      "year" : 2012
    }, {
      "title" : "Application of nanoparticles in oral delivery of immediate release formulations",
      "author" : [ "F. Kesisoglou", "S. Panmai", "Y. Wu" ],
      "venue" : "Current Nanoscience, 3 ",
      "citeRegEx" : "17",
      "shortCiteRegEx" : null,
      "year" : 2007
    }, {
      "title" : "Edible nanoemulsions: fabrication",
      "author" : [ "D.J. McClements" ],
      "venue" : "properties, and functional performance, Soft Matter, 7 ",
      "citeRegEx" : "18",
      "shortCiteRegEx" : null,
      "year" : 2011
    }, {
      "title" : "Bioavailability of nanoparticles in nutrient and nutraceutical delivery",
      "author" : [ "E. Acosta" ],
      "venue" : "Current Opinion in Colloid & Interface Science, 14 ",
      "citeRegEx" : "19",
      "shortCiteRegEx" : null,
      "year" : 2009
    }, {
      "title" : "Biostability enhancement of oil core — polysaccharide multilayer shell via photoinitiator free thiol-ene ‘click’ reaction",
      "author" : [ "V. Calcagno", "R. Vecchione", "A. Sagliano", "A. Carella", "D. Guarnieri", "V. Belli", "L. Raiola", "A. Roviello", "P.A. Netti" ],
      "venue" : "Colloids and Surfaces B: Biointerfaces, 142 ",
      "citeRegEx" : "20",
      "shortCiteRegEx" : null,
      "year" : 2016
    }, {
      "title" : "Tunable stability of monodisperse secondary O/W nano-emulsions",
      "author" : [ "R. Vecchione", "U. Ciotola", "A. Sagliano", "P. Bianchini", "A. Diaspro", "P. Netti" ],
      "venue" : "Nanoscale, 6 ",
      "citeRegEx" : "21",
      "shortCiteRegEx" : null,
      "year" : 2014
    }, {
      "title" : "Thermodynamic Signature of Secondary Nano-Emulsion Formation by Isothermal Titration Calorimetry",
      "author" : [ "I. Fotticchia", "T. Fotticchia", "C.A. Mattia", "P.A. Netti", "R. Vecchione", "C. Giancola" ],
      "venue" : "Langmuir, 30 ",
      "citeRegEx" : "22",
      "shortCiteRegEx" : null,
      "year" : 2014
    }, {
      "title" : "Curcumin–phospholipid complex: preparation",
      "author" : [ "K. Maiti", "K. Mukherjee", "A. Gantait", "B.P. Saha", "P.K. Mukherjee" ],
      "venue" : "therapeutic evaluation and pharmacokinetic study in rats, International journal of pharmaceutics, 330 ",
      "citeRegEx" : "23",
      "shortCiteRegEx" : null,
      "year" : 2007
    }, {
      "title" : "Recent developments in delivery",
      "author" : [ "S. Prasad", "A.K. Tyagi", "B.B. Aggarwal" ],
      "venue" : "bioavailability, absorption and metabolism of curcumin: the golden pigment from golden spice, Cancer research and treatment: official journal of Korean Cancer Association, 46 ",
      "citeRegEx" : "24",
      "shortCiteRegEx" : null,
      "year" : 2014
    }, {
      "title" : "Comparison of systemic availability of curcumin with that of curcumin formulated with phosphatidylcholine",
      "author" : [ "T.H. Marczylo", "R.D. Verschoyle", "D.N. Cooke", "P. Morazzoni", "W.P. Steward", "A.J. Gescher" ],
      "venue" : "Cancer chemotherapy and pharmacology, 60 ",
      "citeRegEx" : "25",
      "shortCiteRegEx" : null,
      "year" : 2007
    }, {
      "title" : "M",
      "author" : [ "A.P. Walczak", "P.J. Hendriksen", "R.A. Woutersen" ],
      "venue" : "van der Zande, A.K. Undas, R. Helsdingen, H.H. van den Berg, I.M. Rietjens, H. Bouwmeester, Bioavailability and biodistribution of differently charged polystyrene nanoparticles upon oral exposure in rats, Journal of Nanoparticle Research, 17 ",
      "citeRegEx" : "26",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "F",
      "author" : [ "K. Loeschner", "J. Navratilova", "C. Købler", "K. Mølhave", "S. Wagner" ],
      "venue" : "von der Kammer, E.H. Larsen, Detection and characterization of silver nanoparticles in chicken meat by asymmetric flow field flow fractionation with detection by conventional or single particle ICP-MS, Analytical and bioanalytical chemistry, 405 ",
      "citeRegEx" : "27",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "Effects of polymer molecular weight on relative oral bioavailability of curcumin",
      "author" : [ "Y.-M. Tsai", "W.-L. Chang-Liao", "C.-F. Chien", "L.-C. Lin", "T.-H. Tsai" ],
      "venue" : "International journal of nanomedicine, 7 ",
      "citeRegEx" : "28",
      "shortCiteRegEx" : null,
      "year" : 2012
    }, {
      "title" : "Caspase‐1‐inhibitor ac‐YVAD‐cmk reduces LPS‐lethality in rats without affecting haematology or cytokine responses",
      "author" : [ "G. Mathiak", "G. Grass", "T. Herzmann", "T. Luebke", "C.C. Zetina", "S.A. Boehm", "H. Bohlen", "L.F. Neville", "A.H. Hoelscher" ],
      "venue" : "British journal of pharmacology, 131 ",
      "citeRegEx" : "29",
      "shortCiteRegEx" : null,
      "year" : 2000
    }, {
      "title" : "Bacterial lipopolysaccharide enhances aflatoxin B1 hepatotoxicity in rats by a mechanism that depends on tumor necrosis factor α",
      "author" : [ "C.C. Barton", "E.X. Barton", "P.E. Ganey", "S.L. Kunkel", "R.A. Roth" ],
      "venue" : "Hepatology, 33 ",
      "citeRegEx" : "30",
      "shortCiteRegEx" : null,
      "year" : 2001
    }, {
      "title" : "Ultrastable Liquid-Liquid Interface as Viable Route for Controlled Deposition of Biodegradable Polymer Nanocapsules",
      "author" : [ "R. Vecchione", "G. Iaccarino", "P. Bianchini", "R. Marotta", "F. D'Autilia", "V. Quagliariello", "A. Diaspro", "P. Netti" ],
      "venue" : "Small, ",
      "citeRegEx" : "31",
      "shortCiteRegEx" : null,
      "year" : 2016
    }, {
      "title" : "Thiomers: a new generation of mucoadhesive polymers",
      "author" : [ "A. Bernkop-Schnürch" ],
      "venue" : "Advanced drug delivery reviews, 57 ",
      "citeRegEx" : "32",
      "shortCiteRegEx" : null,
      "year" : 2005
    }, {
      "title" : "Development of mucoadhesive thiolated chitosan nanoparticles for biomedical applications",
      "author" : [ "A. Anitha", "N. Deepa", "K. Chennazhi", "S. Nair", "H. Tamura", "R. Jayakumar" ],
      "venue" : "Carbohydrate Polymers, 83 ",
      "citeRegEx" : "33",
      "shortCiteRegEx" : null,
      "year" : 2011
    }, {
      "title" : "Curcumin and cancer cells: how many ways can curry kill tumor cells selectively",
      "author" : [ "J. Ravindran", "S. Prasad", "B.B. Aggarwal" ],
      "venue" : "The AAPS journal, 11 ",
      "citeRegEx" : "34",
      "shortCiteRegEx" : null,
      "year" : 2009
    }, {
      "title" : "Synergistic Effect of Curcumin in Combination with Anticancer Agents in Human Retinoblastoma Cancer Cells Lines",
      "author" : [ "S. Sreenivasan", "S. Krishnakumar" ],
      "venue" : "Current eye research, ",
      "citeRegEx" : "35",
      "shortCiteRegEx" : null,
      "year" : 2014
    }, {
      "title" : "Mechanistic evaluation of the signaling events regulating curcumin-mediated chemosensitization of breast cancer cells to 5-fluorouracil",
      "author" : [ "B. Vinod", "J. Antony", "H. Nair", "V. Puliyappadamba", "M. Saikia", "S.S. Narayanan", "A. Bevin", "R.J. Anto" ],
      "venue" : "Cell death & disease, 4 ",
      "citeRegEx" : "36",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "Synergistic anticancer effects of curcumin and resveratrol in Hepa1-6 hepatocellular carcinoma cells",
      "author" : [ "Q. Du", "B. Hu", "H.-M. An", "K.-P. Shen", "L. Xu", "S. Deng", "M.-M. Wei" ],
      "venue" : "Oncology reports, 29 ",
      "citeRegEx" : "37",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "Uptake and cytotoxicity of chitosan molecules and nanoparticles: effects of molecular weight and degree of deacetylation",
      "author" : [ "M. Huang", "E. Khor", "L.-Y. Lim" ],
      "venue" : "Pharmaceutical research, 21 ",
      "citeRegEx" : "38",
      "shortCiteRegEx" : null,
      "year" : 2004
    }, {
      "title" : "Piperine-mediated inhibition of glucuronidation activity in isolated epithelial cells of the guinea-pig small intestine: evidence that piperine lowers the endogeneous UDPglucuronic acid content",
      "author" : [ "J. Singh", "R. Dubey", "C. Atal" ],
      "venue" : "Journal of Pharmacology and Experimental Therapeutics, 236 ",
      "citeRegEx" : "39",
      "shortCiteRegEx" : null,
      "year" : 1986
    }, {
      "title" : "Cancer nanotechnology: opportunities and challenges",
      "author" : [ "M. Ferrari" ],
      "venue" : "Nature Reviews Cancer, 5 ",
      "citeRegEx" : "40",
      "shortCiteRegEx" : null,
      "year" : 2005
    }, {
      "title" : "Emerging cytokine networks in colorectal cancer",
      "author" : [ "N.R. West", "S. McCuaig", "F. Franchini", "F. Powrie" ],
      "venue" : "Nature Reviews Immunology, ",
      "citeRegEx" : "41",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "The role of cytokines in breast cancer development and progression",
      "author" : [ "M. Esquivel-Velázquez", "P. Ostoa-Saloma", "M.I. Palacios-Arreola", "K.E. Nava-Castro", "J.I. Castro", "J. Morales-Montor" ],
      "venue" : "Journal of Interferon & Cytokine Research, 35 ",
      "citeRegEx" : "42",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "Expression of tumour necrosis factor‐alpha (TNF‐α) mRNA and protein in pathological thyroid tissue and carcinoma cell lines",
      "author" : [ "G. Aust", "M. Heuer", "S. Laue", "I. Lehmann", "A. Hofmann", "N.E. HELDIN", "W. Scherbaum" ],
      "venue" : "Clinical & Experimental Immunology, 105 ",
      "citeRegEx" : "43",
      "shortCiteRegEx" : null,
      "year" : 1996
    }, {
      "title" : "Interleukin-1 and cancer progression: the emerging role of interleukin-1 receptor antagonist as a novel therapeutic agent in cancer treatment",
      "author" : [ "A.M. Lewis", "S. Varghese", "H. Xu", "H.R. Alexander" ],
      "venue" : "Journal of translational medicine, 4 ",
      "citeRegEx" : "44",
      "shortCiteRegEx" : null,
      "year" : 2006
    }, {
      "title" : "Interleukin‐8 is associated with proliferation",
      "author" : [ "Y. Ning", "P.C. Manegold", "Y.K. Hong", "W. Zhang", "A. Pohl", "G. Lurje", "T. Winder", "D. Yang", "M.J. LaBonte", "P.M. Wilson" ],
      "venue" : "migration, angiogenesis and chemosensitivity in vitro and in vivo in colon cancer cell line models, International Journal of Cancer, 128 ",
      "citeRegEx" : "45",
      "shortCiteRegEx" : null,
      "year" : 2011
    }, {
      "title" : "Interleukin-6 is a potent growth factor for ER-α-positive human breast cancer",
      "author" : [ "A.K. Sasser", "N.J. Sullivan", "A.W. Studebaker", "L.F. Hendey", "A.E. Axel", "B.M. Hall" ],
      "venue" : "The FASEB Journal, 21 ",
      "citeRegEx" : "46",
      "shortCiteRegEx" : null,
      "year" : 2007
    }, {
      "title" : "Interleukin-6--a key regulator of colorectal cancer development",
      "author" : [ "M.J. Waldner", "S. Foersch", "M.F. Neurath" ],
      "venue" : "Int J Biol Sci, 8 ",
      "citeRegEx" : "47",
      "shortCiteRegEx" : null,
      "year" : 2012
    }, {
      "title" : "Expression of Cytokines and Activation of Transcription Factors in Lipopolysaccharide-Administered Rats and Their Inhibition by PhenylN-tert- Butylnitrone (PBN)",
      "author" : [ "H. Sang", "G.L. Wallis", "C.A. Stewart", "Y. Kotake" ],
      "venue" : "Archives of biochemistry and biophysics, 363 ",
      "citeRegEx" : "48",
      "shortCiteRegEx" : null,
      "year" : 1999
    }, {
      "title" : "Anti-inflammatory activity of cinnamon water extract in vivo and in vitro LPS-induced models",
      "author" : [ "J.-W. Hong", "G.-E. Yang", "Y.B. Kim", "S.H. Eom", "J.-H. Lew", "H. Kang" ],
      "venue" : "BMC complementary and alternative medicine, 12 ",
      "citeRegEx" : "49",
      "shortCiteRegEx" : null,
      "year" : 2012
    }, {
      "title" : "TLR signaling",
      "author" : [ "T. Kawai", "S. Akira" ],
      "venue" : "Cell Death & Differentiation, 13 ",
      "citeRegEx" : "50",
      "shortCiteRegEx" : null,
      "year" : 2006
    } ],
    "referenceMentions" : [ {
      "referenceID" : 0,
      "context" : "powder for the treatment of cough and related respiratory diseases [1] and as an antidysenteric [2].",
      "startOffset" : 67,
      "endOffset" : 70
    }, {
      "referenceID" : 1,
      "context" : "powder for the treatment of cough and related respiratory diseases [1] and as an antidysenteric [2].",
      "startOffset" : 96,
      "endOffset" : 99
    }, {
      "referenceID" : 2,
      "context" : "Moreover, in the past, it was also used to treat dental diseases, digestive disorders such as dyspepsia and acidity, indigestion, flatulence, ulcers and many inflammatory conditions in different body regions [3].",
      "startOffset" : 208,
      "endOffset" : 211
    }, {
      "referenceID" : 3,
      "context" : "Curcumin acts as a ROS scavenger, increases antioxidant glutathione levels by induction of glutamate cysteine ligase, and acts as an antiinflammatory agent through the inhibition of NF-κB signaling [4].",
      "startOffset" : 198,
      "endOffset" : 201
    }, {
      "referenceID" : 4,
      "context" : "Despite its numerous applications, the most relevant issues concerning the pharmacokinetics of curcumin are: molecular instability, poor solubility in water, rapid conjugation to hydrophilic molecules (like glucuronic acid and sulphate) in the liver with biliary excretion and poor enteral absorption [5].",
      "startOffset" : 301,
      "endOffset" : 304
    }, {
      "referenceID" : 5,
      "context" : "To increase its bioavailability, several approaches have been tried: phospholipid complexes (phytosomes), which increased the area under the blood concentration-time curve (AUC) of curcumin after oral administration in rats by 5 times [6]; association with cyclodextrin, with a ten-fold increase in curcumin AUC [7]; BCM-95 extract, whose bioavailability in rats was 7.",
      "startOffset" : 235,
      "endOffset" : 238
    }, {
      "referenceID" : 6,
      "context" : "To increase its bioavailability, several approaches have been tried: phospholipid complexes (phytosomes), which increased the area under the blood concentration-time curve (AUC) of curcumin after oral administration in rats by 5 times [6]; association with cyclodextrin, with a ten-fold increase in curcumin AUC [7]; BCM-95 extract, whose bioavailability in rats was 7.",
      "startOffset" : 312,
      "endOffset" : 315
    }, {
      "referenceID" : 7,
      "context" : "8 times higher than unformulated curcumin [8]; mixing of curcumin with an essential oil obtained from standardized turmeric where AUC was 7–8 times higher than unformulated curcumin [9].",
      "startOffset" : 42,
      "endOffset" : 45
    }, {
      "referenceID" : 8,
      "context" : "8 times higher than unformulated curcumin [8]; mixing of curcumin with an essential oil obtained from standardized turmeric where AUC was 7–8 times higher than unformulated curcumin [9].",
      "startOffset" : 182,
      "endOffset" : 185
    }, {
      "referenceID" : 9,
      "context" : "Another interesting approach to improve the biodistribution of curcumin is based on its combination with piperine, the alkaloid responsible for the pungency of black pepper and long pepper; it inhibits the glucuronidation processes by the enzyme UDP-glucuronosyltransferase (with Ki of 70 μM) in the liver and small intestine, as demonstrated by the administration of unformulated curcumin and piperine [10, 11].",
      "startOffset" : 403,
      "endOffset" : 411
    }, {
      "referenceID" : 10,
      "context" : "Another interesting approach to improve the biodistribution of curcumin is based on its combination with piperine, the alkaloid responsible for the pungency of black pepper and long pepper; it inhibits the glucuronidation processes by the enzyme UDP-glucuronosyltransferase (with Ki of 70 μM) in the liver and small intestine, as demonstrated by the administration of unformulated curcumin and piperine [10, 11].",
      "startOffset" : 403,
      "endOffset" : 411
    }, {
      "referenceID" : 11,
      "context" : "It is also known that oil in water nano-emulsions can provide an anti-inflammatory action as a response to the bioavailability of free curcumin in the blood [12].",
      "startOffset" : 157,
      "endOffset" : 161
    }, {
      "referenceID" : 12,
      "context" : "The best performing nano-emulsion produced so far has provided no more than a ten-fold increase in the AUC compared to unformulated curcumin in mice [13].",
      "startOffset" : 149,
      "endOffset" : 153
    }, {
      "referenceID" : 13,
      "context" : "The best performing system has been up to now based on the use of colloidal curcumin nanoparticles, named 'theracurmin' that showed AUC after oral administration 40-fold higher than that of curcumin powder in rats [14].",
      "startOffset" : 214,
      "endOffset" : 218
    }, {
      "referenceID" : 14,
      "context" : "In particular, we developed and tested biologically, in vitro and in vivo, a new nanometric formulation of curcumin combined with the alkaloid piperine, both loaded in oil in water nanoemulsions stabilized by a layer of chitosan chosen for its resistance to the gastro tract and adhesive properties towards the intestinal lumen [15].",
      "startOffset" : 328,
      "endOffset" : 332
    }, {
      "referenceID" : 15,
      "context" : "Due to the enhanced adhesive properties of the chitosan derivative possessing thiol moieties [16], we optimized the degree of functionalization of chitosan with 2-iminothiolane and tested the system at different degrees of functionalization to quantify its impact.",
      "startOffset" : 93,
      "endOffset" : 97
    }, {
      "referenceID" : 16,
      "context" : "Emulsion size is another important parameter to investigate; although most of the studies report bioavailability improvement with a reduction in nanocarrier size [17, 18], there is evidence that -in some cases- size plays a minor role [19].",
      "startOffset" : 162,
      "endOffset" : 170
    }, {
      "referenceID" : 17,
      "context" : "Emulsion size is another important parameter to investigate; although most of the studies report bioavailability improvement with a reduction in nanocarrier size [17, 18], there is evidence that -in some cases- size plays a minor role [19].",
      "startOffset" : 162,
      "endOffset" : 170
    }, {
      "referenceID" : 18,
      "context" : "Emulsion size is another important parameter to investigate; although most of the studies report bioavailability improvement with a reduction in nanocarrier size [17, 18], there is evidence that -in some cases- size plays a minor role [19].",
      "startOffset" : 235,
      "endOffset" : 239
    }, {
      "referenceID" : 19,
      "context" : "The emulsions were then coated with chitosan (CT, LMW 90-150 kDa, DD 84% determined via 1H-NMR) also purchased from Sigma-Aldrich and purified before use [20].",
      "startOffset" : 154,
      "endOffset" : 158
    }, {
      "referenceID" : 19,
      "context" : "Samples were characterized with 1H NMR spectroscopy and the amount of free thiols was evaluated with the Ellman’s test [20].",
      "startOffset" : 119,
      "endOffset" : 123
    }, {
      "referenceID" : 20,
      "context" : "to room temperature sonication with an immersion sonicator (Ultrasonic Processor VCX500 Sonic and Materials), according to a process protocol previously reported [21, 22].",
      "startOffset" : 162,
      "endOffset" : 170
    }, {
      "referenceID" : 21,
      "context" : "to room temperature sonication with an immersion sonicator (Ultrasonic Processor VCX500 Sonic and Materials), according to a process protocol previously reported [21, 22].",
      "startOffset" : 162,
      "endOffset" : 170
    }, {
      "referenceID" : 20,
      "context" : "The pre-emulsions were finally passed at 2000 bar through the high-pressure valve homogenizer (Microfluidics M110PS) according to the same previous protocol [21].",
      "startOffset" : 157,
      "endOffset" : 161
    }, {
      "referenceID" : 20,
      "context" : "The emulsions coated with chitosan were passed through a high-pressure valve homogenizer at 700 bar for 100 continuous steps, and re-processed after a few days in the same conditions on the same systems (at 700 bar for 100 continuous steps) having found benefit in terms of stability by double redispersion process, as previously reported [21].",
      "startOffset" : 339,
      "endOffset" : 343
    }, {
      "referenceID" : 22,
      "context" : "Curcumin and curcumin-piperine phosphatidylcholine complexes were prepared as described in literature [23].",
      "startOffset" : 102,
      "endOffset" : 106
    }, {
      "referenceID" : 23,
      "context" : "5 ml for the entire experiment; when using piperine, weight ratio between curcumin and piperine was 100/1 w/w, as from literature [24].",
      "startOffset" : 130,
      "endOffset" : 134
    }, {
      "referenceID" : 24,
      "context" : "Studies of AUC 0-120 min of curcumin and curcumin metabolites were performed only up to 2 h guided by similar works in literature [25].",
      "startOffset" : 130,
      "endOffset" : 134
    }, {
      "referenceID" : 25,
      "context" : "Biodistribution study was performed according to literature [26]; briefly, thirty-six male Wistar albino rats (average weight: 400 g) also purchased from Charles River (Calco, Italy), were housed in temperature and humidity-controlled rooms and allowed free access to basal diet and water ad lib for 7 d before starting the experiment.",
      "startOffset" : 60,
      "endOffset" : 64
    }, {
      "referenceID" : 26,
      "context" : "4 during enzymatic digestion) and 5 g/l SDS to improve activity of the enzyme [27].",
      "startOffset" : 78,
      "endOffset" : 82
    }, {
      "referenceID" : 27,
      "context" : "The NE-CT-IT-h-110-FITC concentration was determined based on previously prepared standard calibration curves in each organ separately, obtained by spiking blank organ lysates (prepared as previously described) with serial dilutions of fluorescent nano-emulsions ranging from 0 to 50 mg/ml [28].",
      "startOffset" : 290,
      "endOffset" : 294
    }, {
      "referenceID" : 28,
      "context" : "This timing aimed to obtain the maximum production of pro-inflammatory cytokines after IP administration of LPS in rats, as observed in literature [29, 30].",
      "startOffset" : 147,
      "endOffset" : 155
    }, {
      "referenceID" : 29,
      "context" : "This timing aimed to obtain the maximum production of pro-inflammatory cytokines after IP administration of LPS in rats, as observed in literature [29, 30].",
      "startOffset" : 147,
      "endOffset" : 155
    }, {
      "referenceID" : 20,
      "context" : "In addition, as shown in previous works [21, 31] the process utilized to produce such chitosan coated nano-emulsions allows stability to last longer than 1 year.",
      "startOffset" : 40,
      "endOffset" : 48
    }, {
      "referenceID" : 30,
      "context" : "In addition, as shown in previous works [21, 31] the process utilized to produce such chitosan coated nano-emulsions allows stability to last longer than 1 year.",
      "startOffset" : 40,
      "endOffset" : 48
    }, {
      "referenceID" : 31,
      "context" : "This effect can be explained considering the higher cytoadhesive properties of thiolated polymers due to more interactions with the cellular membrane [32, 33].",
      "startOffset" : 150,
      "endOffset" : 158
    }, {
      "referenceID" : 32,
      "context" : "This effect can be explained considering the higher cytoadhesive properties of thiolated polymers due to more interactions with the cellular membrane [32, 33].",
      "startOffset" : 150,
      "endOffset" : 158
    }, {
      "referenceID" : 33,
      "context" : "Interestingly, comparing results on both cell lines, we observed pronounced toxicity of curcumin against human colon cancer cells in agreement with recent literature sources reporting selective anticancer properties of this molecule alone [34], or in combination with conventional anticancer drugs [35-37].",
      "startOffset" : 239,
      "endOffset" : 243
    }, {
      "referenceID" : 34,
      "context" : "Interestingly, comparing results on both cell lines, we observed pronounced toxicity of curcumin against human colon cancer cells in agreement with recent literature sources reporting selective anticancer properties of this molecule alone [34], or in combination with conventional anticancer drugs [35-37].",
      "startOffset" : 298,
      "endOffset" : 305
    }, {
      "referenceID" : 35,
      "context" : "Interestingly, comparing results on both cell lines, we observed pronounced toxicity of curcumin against human colon cancer cells in agreement with recent literature sources reporting selective anticancer properties of this molecule alone [34], or in combination with conventional anticancer drugs [35-37].",
      "startOffset" : 298,
      "endOffset" : 305
    }, {
      "referenceID" : 36,
      "context" : "Interestingly, comparing results on both cell lines, we observed pronounced toxicity of curcumin against human colon cancer cells in agreement with recent literature sources reporting selective anticancer properties of this molecule alone [34], or in combination with conventional anticancer drugs [35-37].",
      "startOffset" : 298,
      "endOffset" : 305
    }, {
      "referenceID" : 37,
      "context" : "NE-FITC-CT-110-curc were taken up very rapidly by HT29 cell line, with a value of 150 μg of corresponding chitosan per mg cell protein reached after as early as 4 h of incubation; other literature reports confirm the rapidity of cellular uptake due to electrostatic interactions between the cellular membrane and the positively charged chitosan [38].",
      "startOffset" : 345,
      "endOffset" : 349
    }, {
      "referenceID" : 10,
      "context" : "4 and Table 2 confirm the essential role of piperine in the pharmacokinetic profile of curcumin, in agreement with previous works related to the co-administration of unformulated curcumin and piperine [11, 39].",
      "startOffset" : 201,
      "endOffset" : 209
    }, {
      "referenceID" : 38,
      "context" : "4 and Table 2 confirm the essential role of piperine in the pharmacokinetic profile of curcumin, in agreement with previous works related to the co-administration of unformulated curcumin and piperine [11, 39].",
      "startOffset" : 201,
      "endOffset" : 209
    }, {
      "referenceID" : 12,
      "context" : "In conclusion, on the basis of these pharmacokinetic data, co-administering curcumin and piperine in stabilized lipid 110 nm nano-emulsions and coated with chitosan 2-iminothiolane conjugate at the highest degree of modification, we achieved, compared to other pharmacokinetic studies after oral administration in rats, a 6-fold increase in curcumin AUC compared to the most recent nano-emulsion systems [13], and a 1.",
      "startOffset" : 404,
      "endOffset" : 408
    }, {
      "referenceID" : 13,
      "context" : "6-fold increase compared to the best performing system so far reported [14].",
      "startOffset" : 71,
      "endOffset" : 75
    }, {
      "referenceID" : 39,
      "context" : "The general high fluorescence intensity in liver can be justified by the presence of the reticuloendothelial system (RES); in fact, oral delivery along its path unavoidably encounters liver parenchyma where hepatocytes and liver macrophages (Kupffer cells) are able to recognize and metabolize nanocarriers; the same happens at the spleen level [40].",
      "startOffset" : 345,
      "endOffset" : 349
    }, {
      "referenceID" : 40,
      "context" : "Many cytokines and interleukines have been reported to act as anti or pro-inflammatory factors; it has been recently found that these are produced also by cancer cells, or by the tumor microenvironment, in order to develop their progression and survival [41, 42].",
      "startOffset" : 254,
      "endOffset" : 262
    }, {
      "referenceID" : 41,
      "context" : "Many cytokines and interleukines have been reported to act as anti or pro-inflammatory factors; it has been recently found that these are produced also by cancer cells, or by the tumor microenvironment, in order to develop their progression and survival [41, 42].",
      "startOffset" : 254,
      "endOffset" : 262
    }, {
      "referenceID" : 42,
      "context" : "TNF-α is an extremely potent autocrine and paracrine mediator of inflammation and several studies demonstrated its over expression in cancer tissue and carcinoma cell lines [43].",
      "startOffset" : 173,
      "endOffset" : 177
    }, {
      "referenceID" : 43,
      "context" : "Il-1 β is another essential pro inflammatory cytokine that plays a regulatory role in the growth of cancer cells also by autocrine mechanisms [44]; IL-8 a is a pro-inflammatory cytokine with a key role in the initiation and amplification of acute inflammatory reactions [45] and regulation of tumor cell growth and metastasis of thyroid, colon and breast cancer.",
      "startOffset" : 142,
      "endOffset" : 146
    }, {
      "referenceID" : 44,
      "context" : "Il-1 β is another essential pro inflammatory cytokine that plays a regulatory role in the growth of cancer cells also by autocrine mechanisms [44]; IL-8 a is a pro-inflammatory cytokine with a key role in the initiation and amplification of acute inflammatory reactions [45] and regulation of tumor cell growth and metastasis of thyroid, colon and breast cancer.",
      "startOffset" : 270,
      "endOffset" : 274
    }, {
      "referenceID" : 45,
      "context" : "IL-6 is a cytokine whose hypersecretion by tumor microenvironment induces proliferation and a more aggressive phenotype, for example, in ER-positive breast cancer cells [46]; it is also well known that an increased IL-6 expression is related to an advanced stage of disease and decreased survival in colorectal cancer patients [47].",
      "startOffset" : 169,
      "endOffset" : 173
    }, {
      "referenceID" : 46,
      "context" : "IL-6 is a cytokine whose hypersecretion by tumor microenvironment induces proliferation and a more aggressive phenotype, for example, in ER-positive breast cancer cells [46]; it is also well known that an increased IL-6 expression is related to an advanced stage of disease and decreased survival in colorectal cancer patients [47].",
      "startOffset" : 327,
      "endOffset" : 331
    }, {
      "referenceID" : 29,
      "context" : "These cytokines were used, both in cellular and animal studies, as mediators of molecules present in the outer membranes of Gram-negative bacteria [30, 48].",
      "startOffset" : 147,
      "endOffset" : 155
    }, {
      "referenceID" : 47,
      "context" : "These cytokines were used, both in cellular and animal studies, as mediators of molecules present in the outer membranes of Gram-negative bacteria [30, 48].",
      "startOffset" : 147,
      "endOffset" : 155
    }, {
      "referenceID" : 48,
      "context" : "The increase in plasma concentration of the analysed interleukins is in agreement with literature [49], and is mainly related to the TLR4 receptor stimulation by LPS with subsequent induction of cytokines and interleukine production [50].",
      "startOffset" : 98,
      "endOffset" : 102
    }, {
      "referenceID" : 49,
      "context" : "The increase in plasma concentration of the analysed interleukins is in agreement with literature [49], and is mainly related to the TLR4 receptor stimulation by LPS with subsequent induction of cytokines and interleukine production [50].",
      "startOffset" : 233,
      "endOffset" : 237
    } ],
    "year" : 2016,
    "abstractText" : "Although nanocarriers can enhance the bioavailability of free curcumin in the blood, a systematic study on the parameters that affect such enhancement is still missing. In this work we focused the attention on a nanocarrier represented by an oil in water nano-emulsion coated with a thiol modified chitosan and carried out a comprehensive study on the effects that parameters such as size, co-delivery of piperine and degree of chitosan modification can exert on curcumin bioavailability and quantified their impact. We obtained an unprecedented pharmacokinetic profile of curcumin with the best formulation, represented by a combination of a small nanoemulsion size (110 nm), co-delivery of curcumin and piperine (weight ratio 100:1) and a high degree of chitosan thiolation (14-15%). Then, we assessed its anti-inflammatory properties after oral administration in rats at low doses (≤ 0.1 times the volume administered in the pharmacokinetic study). Furthermore, the proposed food grade nano-emulsions loaded with curcumin did not show any cytotoxic effect on normal fibroblasts, while they were able to promote death in colon cancer cells in agreement with the common knowledge of the selective action of curcumin.",
    "creator" : "Elsevier"
  }
}